Novel immunotheranostic FAP-inhibitor target modules for imaging and elimination of FAP-positive cells by UniCAR T-cells.
Saved in:
| Title: | Novel immunotheranostic FAP-inhibitor target modules for imaging and elimination of FAP-positive cells by UniCAR T-cells. |
|---|---|
| Authors: | Boutier H; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Kogler J; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; TUD Dresden University of Technology, School of Science, Faculty of Chemistry and Food Chemistry, Dresden, Germany., Loureiro LR; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Neuber C; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Berndt N; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Arndt C; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany., Stadlbauer S; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; TUD Dresden University of Technology, School of Science, Faculty of Chemistry and Food Chemistry, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden, Germany., Stephan H; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Feldmann A; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden, Germany.; National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology & Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Germany., Kopka K; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; TUD Dresden University of Technology, School of Science, Faculty of Chemistry and Food Chemistry, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden, Germany.; National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology & Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Germany., Hagemeyer CE; Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia., Bachmann M; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden, Germany.; National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology & Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, TUD, Dresden, Germany. |
| Source: | Oncoimmunology [Oncoimmunology] 2025 Dec 31; Vol. 14 (1), pp. 2598908. Date of Electronic Publication: 2025 Dec 15. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
